Outlook Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-09-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$1M
Cost of Revenue
$1M
Gross Profit
$57K
R&D
$27M
SG&A
$40M
D&A
$117K
Operating Income
$-67M
EBITDA
$-67M
Interest Expense
$3M
Interest Income
$90K
Other Income/Expense
$3M
Pretax Income
$-64M
Tax Provision
$-2M
Net Income
$-62M
Gross Margin
4.0%
Operating Margin
-4744.3%
Net Margin
-4416.2%
Effective Tax Rate
2.4%
Deferred Tax Assets
$48K
Deferred Tax Liabilities
—
DTA Valuation Allowance
$146M
Tax Credit Carryforwards
$12M
NOL Carryforwards
$110M
ETR (Continuing Operations)
2.4%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.1%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$76K
Revenue YoY Variation
144.8%
Income YoY Variation
6.5%